The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-26 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
ventral) side of the thorax, and the assumption that injecting venom in the prey's abdomen leads to venom dilution due to the mixing of fluids in the circulatory system and the guts; the distance where the venom has to travel to be effective also increases, making it less efficient in disabling the prey. Two other concepts have been suggested to explain the reason for prey orientation - one suggested that venom is an expensive product to produce, hence venom conservation is essential; and the other concept suggested that striking the prey in that specific position (i.e. aligning the prey as the same orientation of the centipede) would allow the centipede to sufficiently restraint the prey until the venom takes effect.
Hypothermia, especially during winter months Metabolic disruption including hypoglycemia, hyponatremia, acidosis, and hypercalcemia Respiratory compromise including hypoxemia and hypercapnia Infections including pneumonia, cellulitis, and urosepsis Congestive heart failure Cerebrovascular accidents Gastrointestinal bleeding Trauma, motor vehicle accidents, and fractures Medications including anesthetics, sedatives, tranquilizers, narcotics, amiodarone, and lithium Withdrawal of thyroid supplements, especially in relation to a hospitalization Other precipitating factors include:
On the same day, China's special representative for Afghanistan, Yu Xiaoyong, told Taliban Foreign Minister Amir Khan Muttaqi that China had contacted Pakistan and was working to reduce tensions between the Taliban and Pakistan. On 9 March, Taliban officials said that they had destroyed a border outpost of Pakistani forces in the Goshta District of Nangarhar province. On the same day, Pakistani officials stated that their ground forces had destroyed an Afghan Taliban border outpost along the border, while the PAF destroyed an ammunition depot at Shaheen Base in Paktika province. On the same day, Pakistan's Information Minister said that Pakistan's military operations inside Afghanistan were aimed at militant hideouts and did not target civilian areas. He said the strikes were based on precise intelligence, dismissed casualty figures released by the Taliban as fabricated, and argued that United Nations reports of civilian casualties relied largely on information provided by the Taliban administration. On 10 March, Pakistani officials stated that they had destroyed important posts and centers of Taliban forces in the Arandu and Kurram sectors, forcing them to abandon their positions. Taliban officials said that Pakistani forces had carried out strikes in parts of Paktika, Paktia, Khost, and Nuristan provinces, killing three civilians and injuring three others. In Pakistan's Mohmand district, Pakistani Taliban militants clashed with police, resulting in no casualties on either side. A soldier was killed and eight injured in a militant attack in Kurram District.
Sources: en.wikipedia.org
In plants, algae, cyanobacteria, and phototrophic and chemoautotrophic Pseudomonadota (formerly referred to as proteobacteria), the enzyme usually consists of two types of protein subunit, called the large chain (L, about 55,000 Da) and the small chain (S, about 13,000 Da). The large-chain gene (rbcL) is encoded by the chloroplast DNA in plants. There are typically several related small-chain genes in the nucleus of plant cells, and the small chains are imported to the stromal compartment of chloroplasts from the cytosol by crossing the outer chloroplast membrane. The enzymatically active substrate (ribulose 1,5-bisphosphate) binding sites are located in the large chains that form dimers in which amino acids from each large chain contribute to the binding sites. A total of eight large chains (= four dimers) and eight small chains assemble into a larger complex of about 540,000 Da. In some Pseudomonadota and dinoflagellates, enzymes consisting of only large subunits have been found. Magnesium ions (Mg2+) are needed for enzymatic activity. Correct positioning of Mg2+ in the active site of the enzyme involves addition of an "activating" carbon dioxide molecule (CO2) to a lysine in the active site (forming a carbamate). Mg2+ operates by driving deprotonation of the Lys210 residue, causing the Lys residue to rotate by 120 degrees to the trans conformer, decreasing the distance between the nitrogen of Lys and the carbon of CO2. The close proximity allows for the formation of a covalent bond, resulting in the carbamate.
At the time, "yeast nucleic acid" (RNA) was thought to occur only in plants, while "thymus nucleic acid" (DNA) only in animals. The latter was thought to be a tetramer, with the function of buffering cellular pH. In 1937, William Astbury produced the first X-ray diffraction patterns that showed that DNA had a regular structure. In 1943, Oswald Avery, along with co-workers Colin MacLeod and Maclyn McCarty, identified DNA as the transforming principle, supporting Griffith's suggestion (Avery–MacLeod–McCarty experiment). Erwin Chargaff developed and published observations now known as Chargaff's rules, stating that in DNA from any species of any organism, the amount of guanine should be equal to cytosine and the amount of adenine should be equal to thymine.
Sugiol is a protic molecule. Protic molecules are those that have protic groups or hydrogen molecules that readily leave the molecule, such as -OH, -NH, and -HF. These molecules can complicate GC/MS data by increasing peak tailing and affecting the ease with which they can be separated by the GC. In order to avoid this effect, protic molecules are often subjected to derivatization reactions, in which the offending protons are replaced by a different functional group. A commonly used replacement group is trimethylsilyl (TMS), which produces trimethylsilyl derivatives of the original protic molecules. Another commonly used group is tert-butyldimethylsilyl (TBDMS), also used to derivatize hydroxyl and amine protic groups. Diazomethane has also been used to form methyl esters from carboxylic acids.
Sources: en.wikipedia.org
== Awards received while alive == In 1919, she was awarded the Notable Service Medal by President Herbert Hoover for her work in refrigeration. In 1940, she became the second recipient of the Garvan–Olin Medal, then called the Francis P. Garvan Medal, from the American Chemical Society.
Studies of food processing impact on public health and other outcomes, such as affordability, energy efficiency, food safety and sustainability benefit from the use of FPL. Several food ingredients, which have different FPL, are often used in food products. The highest FPL used to obtain ingredients for intermittent processing of formulated foods and the FPL of final processing, whichever is the highest, indicates the FPL of the final food. Final food products may be formulated using ingredients from several FPL which, when including ingredients or processing at FPL 3 and 4, are assigned to the highest FPL 4.
==== MeSH D08.811.074 – dna repair enzymes ==== MeSH D08.811.074.124 – deoxyribodipyrimidine photo-lyase MeSH D08.811.074.249 – dna glycosylases MeSH D08.811.074.249.500 – DNA-formamidopyrimidine glycosylase MeSH D08.811.074.249.750 – thymine dna glycosylase MeSH D08.811.074.249.875 – uracil-dna glycosidase MeSH D08.811.074.500 – dna ligases MeSH D08.811.074.750 – DNA-(apurinic or apyrimidinic site) lyase MeSH D08.811.074.781 – muts dna mismatch-binding protein MeSH D08.811.074.812 – muts homolog 2 protein MeSH D08.811.074.875 – polynucleotide 5'-hydroxyl-kinase
== Discovery == Since the 1960s, seryl-tRNA synthetases have been described in various eukaryotic species, in both biochemical and structural analyses. It was not until 1997 that human SARS and its enzyme product were isolated and expressed in Escherichia coli by a team from The European Molecular Biology Laboratory in France.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.